Journal article · 2025 · Open access
Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial
Nature Medicine, 32(1), 353–361 · Published 1 December 2025 · DOI 10.1038/s41591-025-04106-7
In brief
“Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial” is a 2025 journal article by Paul Edison and 45 co-authors, published in Nature Medicine. OpenAlex counts 120 citations as of 17 November 2026, which puts it in the top 7% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Nature Medicine.
- Citations
- 120
- Most cited in
- 2026 (118)
- Field-weighted impact
- 29.28
- References
- 47
- Authors
- 46
Abstract
Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models. In this study, we aimed to evaluate the safety and efficacy of liraglutide in mild to moderate Alzheimer's disease syndrome. 'Evaluating liraglutide in Alzheimer's disease' (ELAD) is a multicenter, randomized, double-blind, placebo-controlled phase 2b trial in 204 participants with mild to moderate Alzheimer's disease syndrome with no diabetes. Participants received daily injections of liraglutide or placebo for 52 weeks. They underwent fluorodeoxyglucose positron emission tomography, magnetic resonance imaging and detailed neuropsychometric evaluations. The primary outcome was a change in cerebral glucose metabolic rate. Secondary outcomes were safety and tolerability and cognitive changes. The primary outcome showed no significant differences in cerebral glucose metabolism (difference = -0.17; 95% confidence interval: -0.39 to 0.06; P = 0.14) between the two groups. The secondary outcome-score on the Alzheimer's Disease Assessment Scale-Executive domain (ADAS-Exec)-performed better in liraglutide-treated patients compared to placebo (0.15; 95% confidence interval: 0.03-0.28; unadjusted P = 0.01). No significant differences were observed in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) (-0.58; 95% confidence interval: -3.13 to 1.97; unadjusted P = 0.65) or Clinical Dementia Rating-Sum of Boxes (CDR-SoB) (-0.06; 95% confidence interval: -0.57 to 0.44; unadjusted P = 0.81) scores. Liraglutide was generally safe and well tolerated in non-diabetic patients with Alzheimer's disease. ClinicalTrials.gov identifier: NCT01843075 .
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Edison, P., Femminella, G. D., Ritchie, C. W., Nowell, J., Holmes, C., Walker, Z., Ridha, B. H., Raza, S., Livingston, N. R., Frangou, E., Love, S., Williams, G., Lawrence, R., McFarlane, B., Archer, H. A., Coulthard, E. J., Underwood, B. R., Koranteng, P., Karim, S., . . . Ballard, C. G. (2025). Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nature Medicine, 32(1), 353–361. https://doi.org/10.1038/s41591-025-04106-7
MLA 9
Edison, Paul, et al. “Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial.” Nature Medicine, vol. 32, no. 1, 2025, pp. 353–361. https://doi.org/10.1038/s41591-025-04106-7.
Chicago
Edison, Paul, Grazia Daniela Femminella, Craig William Ritchie, Joseph Nowell, Clive Holmes, Zuzana Walker, Basil H. Ridha, et al. 2025. “Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial.” Nature Medicine 32 (1): 353–361. https://doi.org/10.1038/s41591-025-04106-7.
Harvard
Edison, P. et al. (2025) ‘Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial’, Nature Medicine, 32(1), pp. 353–361. doi:10.1038/s41591-025-04106-7.
IEEE
P. Edison et al., “Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial,” Nature Medicine, vol. 32, no. 1, pp. 353–361, 2025, doi: 10.1038/s41591-025-04106-7.
BibTeX
@article{edison2025liraglutide,
title = {{Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial}},
author = {Edison, Paul and Femminella, Grazia Daniela and Ritchie, Craig William and Nowell, Joseph and Holmes, Clive and Walker, Zuzana and Ridha, Basil H. and Raza, Sanara and Livingston, Nicholas R and Frangou, Eleni and Love, Sharon and Williams, Gareth and Lawrence, Robert and McFarlane, Brady and Archer, Hilary Anne and Coulthard, Elizabeth Jane and Underwood, Benjamin R. and Koranteng, Paul and Karim, Salman and Bannister, Carol and Perneczky, Robert and Prasanna, Aparna and Junaid, Kehinde and McGuinness, Bernadette and Nilforooshan, Ramin and Macharouthu, Ajay and Donaldson, Andrew J. and Thacker, Simon and Russell, Gregor and Malik, Naghma and others},
journal = {Nature Medicine},
year = {2025},
volume = {32},
number = {1},
pages = {353--361},
doi = {10.1038/s41591-025-04106-7},
url = {https://doi.org/10.1038/s41591-025-04106-7}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- liraglutide
- Alzheimer's disease
- GLP-1 receptor agonists
- brain glucose metabolism
- neuroprotection
- executive function
- activities of daily living
- cognitive decline
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Edison, P., Femminella, G. D., Ritchie, C. W., Nowell, J., Holmes, C., Walker, Z., Ridha, B. H., Raza, S., Livingston, N. R., Frangou, E., Love, S., Williams, G., Lawrence, R., McFarlane, B., Archer, H. A., Coulthard, E. J., Underwood, B. R., Koranteng, P., Karim, S., . . . Ballard, C. G. (2025). Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nature Medicine, 32(1), 353–361. https://doi.org/10.1038/s41591-025-04106-7
How many times has this paper been cited?
120 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Paul Edison, Grazia Daniela Femminella, Craig William Ritchie, Joseph Nowell, Clive Holmes, Zuzana Walker, Basil H. Ridha, Sanara Raza, Nicholas R Livingston, Eleni Frangou, Sharon Love, Gareth Williams and 34 more.
What is the DOI of this paper?
10.1038/s41591-025-04106-7, permanently at https://doi.org/10.1038/s41591-025-04106-7. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.